avacopan (Rx)

Brand and Other Names:Tavneos
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

capsule

  • 10mg

ANCA–associated Vasculitis

Indicated as adjunctive treatment of severe active antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with glucocorticoids

Note: Does not eliminate glucocorticoid use

30 mg PO BID with food

Dosage Modifications

Renal impairment

  • Mild, moderate, or severe: No dosage adjustment necessary

Hepatic impairment

  • Mild-to-moderate (Child-Pugh A or B): No dosage adjustment necessary
  • Severe (Child-Pugh C): Not recommended

Coadministration with strong CYP3A4 inhibitors

  • Reduce dose to 30 mg qDay

Dosing Considerations

Monitoring

  • Obtain liver test panel (ALT, AST, alkaline phosphatase, total bilirubin) before initiating and q4Weeks after starting therapy for first 6 months, and then as clinically indicated
  • Hepatitis B (HBV) serology: Screen for HBV infection by measuring HBsAg and anti-HBc before initiating and for 6 months after starting treatment
  • For patients with evidence of prior or current HBV infection, refer to physician with expertise in managing hepatitis B regarding monitoring and consideration for HBV antiviral therapy before or during treatment

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and avacopan

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (0)

                  Minor (0)

                    Previous
                    Next:

                    Adverse Effects

                    >10%

                    Nausea (23.5%)

                    Headache (20.5%)

                    Hypertension (18.1%)

                    Diarrhea (15.1%)

                    Vomiting (15.1%)

                    Hepatic-related adverse reactions (13.3%)

                    Rash (11.4%)

                    Fatigue (10.2%)

                    1-10%

                    Upper abdominal pain (6.6%)

                    Dizziness (6.6%)

                    Blood creatinine increased (6%)

                    Paresthesia (5.4%)

                    Elevated creatine phosphokinase (3.6%)

                    Angioedema (1.2%)

                    Previous
                    Next:

                    Warnings

                    Contraindications

                    Hypersensitivity to avacopan or excipients

                    Cautions

                    May cause angioedema; if angioedema occurs, discontinue avacopan immediately, provide appropriate therapy, and monitor for airway compromise; do not readminister unless another cause has been established

                    Serious infection

                    • Serious infections, including fatal infections, reported; common infections reported included pneumonia and urinary tract infections
                    • Avoid use with active, serious infection, including localized infections
                    • Closely monitor for signs and symptoms of infection during and after treatment; interrupt treatment if a serious or opportunistic infection develops
                    • If a new infection develops during treatment, promptly complete diagnostic testing appropriate for an immunocompromised patient; initiate appropriate antimicrobial therapy and closely monitor
                    • Interrupt treatment if unresponsive to antimicrobial therapy; may resume once infection controlled
                    • Consider risks and benefits before initiating in patients
                      • With chronic or recurrent infection
                      • Who have been exposed to tuberculosis
                      • With history of serious or opportunistic infection
                      • Who have resided or traveled in areas of endemic tuberculosis or endemic mycoses
                      • With underlying conditions that may predispose them to infection

                    HBV reactivation

                    • Hepatitis B virus (HBV) reactivation, including life-threatening hepatitis B, observed during clinical trials
                    • Reactivation of HBV replication is often followed by hepatitis; in severe cases, increase in bilirubin levels, liver failure, and death can occur
                    • Screen patients for HBV infection by measuring HBsAg and anti-HBc before initiating
                    • Refer to specialist if patient shows evidence of prior HBV infection to consider HBV antiviral therapy before and/or during avacopan treatment
                    • Insufficient data exist regarding safety of resuming avacopan in patients who develop HBV reactivation; consult specialist regarding resumption in patients whose HBV reactivation resolves

                    Hepatotoxicity

                    • Serious cases of hepatic injury observed; monitor closely for hepatic adverse reactions
                    • During controlled trials, a higher incidence of transaminase elevations and hepatobiliary events, including serious and life-threatening events, were reported
                    • Monitor liver enzymes before and during treatment
                    • ALT or AST >3x ULN: Evaluate promptly and consider pausing treatment as clinically indicated
                    • AST or ALT >5x ULN or AST or ALT >3x ULN with bilirubin >2x ULN: Discontinue until avacopan-induced liver injury is ruled out
                    • Not recommended with active, untreated, and/or uncontrolled chronic liver disease (eg, chronic active hepatitis B, untreated hepatitis C, uncontrolled autoimmune hepatitis) and cirrhosis

                    Drug interaction overview

                    • CYP3A4 substrate (major); shows induction and time-dependent inhibition of CYP3A4
                    • Strong CYP3A4 inhibitors
                      • Decrease avacopan dose
                      • Coadministration with strong CYP3A4 inhibitor increases avacopan systemic exposure
                    • Moderate and strong CYP3A4 inducers
                      • Avoid coadministration
                      • Coadministration with moderate or strong CYP3A4 inducers decreases avacopan systemic exposure
                    • CYP3A4 substrates
                      • Closely monitor CYP3A4 substrates with a narrow therapeutic window; consider dose reduction
                      • Avacopan inhibits CYP3A4 substrates
                    Previous
                    Next:

                    Pregnancy & Lactation

                    Pregnancy

                    There are no adequate and well-controlled studies in pregnant females to inform a drug-associated risk

                    Increased number of spontaneous abortions in rabbits observed

                    Animal data

                    • Oral administration to pregnant hamsters and rabbits during organogenesis produced no evidence of fetal harm with exposures up to ~5 and 0.6 times, respectively, the exposure at the maximum recommended human dose (MRHD)
                    • Avacopan caused increased abortions in rabbits at an exposure 0.6 times the MRHD

                    Lactation

                    Data are not available on secretion in human milk, effects on breastfed children, or on milk production

                    Consider developmental and health benefits of breastfeeding along with the mother’s clinical need for avacopan and any potential adverse effects on the breastfed infant from avacopan or from the underlying maternal condition

                    Animal data

                    • Avacopan has not been measured in the milk of lactating animals; however, it was detected in the plasma of nursing offspring in a prenatal and postnatal development study with hamsters at a pup-to-maternal plasma ratio of 0.37

                    Pregnancy Categories

                    A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                    B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                    C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                    D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                    X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                    NA: Information not available.

                    Previous
                    Next:

                    Pharmacology

                    Mechanism of Action

                    Complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a

                    Avacopan blocks C5a-mediated neutrophil activation and migration

                    Precise mechanism by which avacopan exerts its therapeutic effect in ANCA-associated vasculitis has not been definitively established

                    Absorption

                    Steady-state plasma levels

                    • Reached by 13 weeks; accumulation ~4-fold
                    • Peak plasma concentration: 349 ng/mL
                    • AUC0-12hr: 3466 ng⋅h/mL

                    Food

                    • Coadministration with high-fat, high-calorie meal increases AUC and peak plasma concentration by ~72% and 8%, respectively, and delays peak plasma time by ~4 hr (from 2 hr to 6 hr)

                    Distribution

                    Protein bound: >99.9% (parent and metabolite)

                    Vd: 345 L

                    Metabolism

                    Major enzyme for avacopan and metabolite clearance: CYP3A4

                    Major circulating metabolite: M1, a mono-hydroxylated, present at ~12% of total drug-related materials in plasma; has approximately same activity as avacopan on C5a receptor

                    Elimination

                    Half-life: 97.6 hr (avacopan); 55.6 hr (M1)

                    Clearance: 16.3 L/hr

                    Excretion: Feces 77% (7% unchanged); urine 10% (<0.1% unchanged)

                    Previous
                    Next:

                    Administration

                    Oral Administration

                    Take with food

                    Swallow capsules whole; do not crush, chew, or open

                    Missed dose

                    • If dose missed, wait until usual scheduled time to take the next dose
                    • Instruct patient not to double the next dose

                    Storage

                    Store at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF)

                    Previous
                    Next:

                    Images

                    No images available for this drug.
                    Previous
                    Next:

                    Patient Handout

                    A Patient Handout is not currently available for this monograph.
                    Previous
                    Next:

                    Formulary

                    FormularyPatient Discounts

                    Adding plans allows you to compare formulary status to other drugs in the same class.

                    To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                    Adding plans allows you to:

                    • View the formulary and any restrictions for each plan.
                    • Manage and view all your plans together – even plans in different states.
                    • Compare formulary status to other drugs in the same class.
                    • Access your plan list on any device – mobile or desktop.

                    The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                    Tier Description
                    1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                    2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                    3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                    4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    NC NOT COVERED – Drugs that are not covered by the plan.
                    Code Definition
                    PA Prior Authorization
                    Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                    QL Quantity Limits
                    Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                    ST Step Therapy
                    Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                    OR Other Restrictions
                    Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                    Additional Offers
                    Email to Patient

                    From:

                    To:

                    The recipient will receive more details and instructions to access this offer.

                    By clicking send, you acknowledge that you have permission to email the recipient with this information.

                    Email Forms to Patient

                    From:

                    To:

                    The recipient will receive more details and instructions to access this offer.

                    By clicking send, you acknowledge that you have permission to email the recipient with this information.

                    Previous
                    Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.